🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)
China flag China · Delayed Price · Currency is CNY
37.47
-0.68 (-1.78%)
Nov 20, 2026, 3:00 PM CST

SHA:600329 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
4,6454,8977,2928,2068,2316,892
Other Revenue
20.7320.7314.2516.2317.8715.33
4,6654,9177,3078,2228,2496,908
Revenue Growth
-13.05%-32.70%-11.13%-0.33%19.42%4.60%
Cost of Revenue
1,2421,3123,8044,6324,9924,161
Gross Profit
3,4243,6053,5033,5903,2582,747
Selling, General & Admin
2,0512,4172,4592,5082,3471,930
Research & Development
209.95189.81162.38184.63153.15161.05
Other Operating Expenses
97.772.7763.4457.2876.6964.12
Operating Expenses
2,3662,6872,7292,7692,5862,160
Operating Income
1,058917.86774.04821.03671.32587.04
Interest Expense
-9-9.16-40.2-35.85-10.27-2.94
Interest & Investment Income
1,6581,6881,937362.75330.35263.97
Currency Exchange Gain (Loss)
-0.8-0.8-1.51-1.13-2.440.69
Other Non Operating Income (Expenses)
-8.93-2.08-2.55-2.713.63-5.3
EBT Excluding Unusual Items
2,6922,5932,6661,144992.59843.46
Impairment of Goodwill
-12.3-12.3-53.61-18.78-19.57-
Gain (Loss) on Sale of Investments
-1,541-----
Gain (Loss) on Sale of Assets
-14.742.640.07-0.480.6710.39
Asset Writedown
-105.21-105.21-60.16-24.95-0.18-
Other Unusual Items
8.958.9526.13-4.516.6718.96
Pretax Income
1,0282,4872,5791,095980.19872.81
Income Tax Expense
150.54376.7363.56126.66106.9385.93
Earnings From Continuing Operations
877.272,1112,215968.71873.26786.88
Minority Interest in Earnings
18.420.2714.1218-11.46-17.73
Net Income
895.672,1312,229986.71861.79769.14
Net Income to Common
895.672,1312,229986.71861.79769.14
Net Income Growth
-74.97%-4.41%125.94%14.49%12.05%16.24%
Shares Outstanding (Basic)
771769769771769769
Shares Outstanding (Diluted)
771769771771776769
Shares Change
0.33%-0.27%0.07%-0.71%0.94%-0.04%
EPS (Basic)
1.162.772.901.281.121.00
EPS (Diluted)
1.162.772.891.281.111.00
EPS Growth
-75.05%-4.15%125.78%15.32%11.00%16.28%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,114342.45806.86547.56569.34695.45
Free Cash Flow Per Share
1.450.451.050.710.730.90
Dividend Per Share
2.3404.7901.2801.2801.1200.500
Dividend Growth
-37.27%274.22%0%14.29%124.00%66.67%
Gross Margin
73.39%73.31%47.94%43.66%39.49%39.77%
Operating Margin
22.68%18.67%10.59%9.98%8.14%8.50%
Profit Margin
19.20%43.34%30.51%12.00%10.45%11.13%
Free Cash Flow Margin
23.87%6.96%11.04%6.66%6.90%10.07%
EBITDA
1,1711,026895.56947.65786.15701.29
EBITDA Margin
25.09%20.87%12.26%11.53%9.53%10.15%
D&A For EBITDA
112.57108.58121.52126.62114.83114.25
EBIT
1,058917.86774.04821.03671.32587.04
EBIT Margin
22.68%18.67%10.59%9.98%8.14%8.50%
Effective Tax Rate
14.65%15.14%14.10%11.56%10.91%9.84%
Revenue as Reported
4,9174,9177,3078,2228,2496,908
Advertising Expenses
---437.2-321.16